Efficacy

Efficacy of Tecentriq (Atezolizumab) in Lung Cancer

Tecentriq (Atezolizumab) is a monoclonal antibody designed to bind with the programmed death-ligand 1 (PD-L1), which is expressed on tumor cells and tumor-infiltrating immune cells. By blocking the interaction between PD-L1 and its receptors PD-1 and B7.1, Tecentriq may enable the activation of T cells, which can then attack the cancer cells. In non-small cell lung cancer (NSCLC), Tecentriq has shown efficacy as both a monotherapy and in combination with other treatments. In particular, it has been approved for use in patients with metastatic NSCLC with high PD-L1 expression and no EGFR or ALK genomic tumor aberrations, demonstrating improvements in overall survival compared to chemotherapy alone.

Additionally, Tecentriq has been studied in small cell lung cancer (SCLC). It has been approved for use in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage SCLC. Clinical trials have shown that this combination can lead to a significant improvement in overall survival and progression-free survival when compared to chemotherapy alone. This marks a notable advancement in the treatment of a particularly aggressive form of lung cancer.

Efficacy of Enhertu (fam-trastuzumab deruxtecan-nxki) in Lung Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate consisting of a humanized anti-HER2 antibody, a stable linker, and a cytotoxic topoisomerase I inhibitor payload. It is designed to target and deliver chemotherapy directly to cancer cells that overexpress HER2. While traditionally associated with breast cancer, HER2 mutations are also present in a subset of non-small cell lung cancers (NSCLC). Enhertu has shown promising results in patients with HER2-mutant NSCLC. In clinical studies, patients treated with Enhertu demonstrated a significant response rate, with many experiencing tumor shrinkage. This has provided a new treatment avenue for patients with this specific molecular alteration in lung cancer.

The efficacy of Enhertu in lung cancer patients with HER2 overexpression or mutations suggests a potential shift in the treatment landscape for this challenging disease. As a targeted therapy, Enhertu offers a more personalized approach to cancer treatment, which is particularly valuable in lung cancer where the molecular profile of the tumor can significantly influence the choice and success of treatment. Ongoing clinical trials continue to evaluate the long-term benefits and optimal use of Enhertu in various settings of lung cancer care.